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A high-performance liquid chromatography (HPLC) method was developed and validated for simultaneous determination of 
resveratrol (RSV) and lipoic acid (LA). A C18 column was used with a mobile phase consisting of acetonitrile and 0.01M 
phosphoric acid (60:40). The detection wavelength was at 235 nm. The method was specific in the presence of pharmaceutical 
excipients widely used in solid dosage forms or lipid-core nanocapsules. The results demonstrated linearity between 5 and 50 
µg/mL for RSV and 30 and 120 µg/mL for LA. The method presented precision and accuracy (RSD <5%). In addition, the 
developed method was considered robust. Therefore, the developed method can be applied successfully for simultaneous 
determination of RSV and LA in the proposed conditions, with a potential application to assay both drugs in several dosage forms. 
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Introduction 
 
Antioxidants can decrease or inactivate 
free radicals and/or reduce oxidative damage (1). 
Polyphenols are a group of antioxidants widely 
used as treatment in many diseases. Resveratrol 
(RSV) (Figure 1a) is a natural polyphenol found 
mostly in grapes and wine (2). Recently, studies 
demonstrated that RSV has many biological 
activities, including cardioprotective (3), 
chemopreventing (4), neuroprotective (5), anti-
inflammatory (6) and antioxidanteffects (7). 
Similarly, Lipoic Acid (LA) (Figure 1b) is 
a potent antioxidant with reactive oxygen species 
scavenging activity, ability to repair other 
antioxidants (such as ascorbic acid, α-tocoferol 
and glutathione) in physiological and 
physiopathological in vivo conditions and can also 
chelate metals (8,9). LA can prevent sun damage 
aging, helping lesion recovery (10), preventing 
inflammation of the skin and a 
photocarcinogenesis caused by ultraviolet 
radiation (11). Thus, LA  emerges as a potent 
antioxidant drug and also can be used in 
association with other antioxidants as it has the 
ability to interact with them and help their 
recovery (12). 
The association of antioxidants with 
different mechanisms of action shows potential for 
use in a variety of pharmaceutical applications. 
This strategy aims a synergic effect from drugs. 
Also, the use of antioxidants in association with 
conventional therapies is an interesting approach, 
being able to increase drug effect and/or protect 
healthy cells from some drug’s toxicity (13,14). 
The association of RSV and LA is promising 
because of RSV’s pharmacological properties and 
LA’s protection effects besides its capacity to 
interact with other antioxidants. It has been 
described that this association has neuroprotective 
effects, resulting from the effect of both drugs on 
multiple pathways (15), being of potential interest 
in combined therapy and association in 
pharmaceutical formulations. 
 
 
 
 
Figure 1. Chemical structures of (a) RSV and (b) LA. 
 
 A simultaneous analysis of two or more 
components in pharmaceutical dosage forms 
without prior chemical separation is an analytical 
challenge (16). In this way, a validation of 
analytical methods for simultaneous detection of 
drugs is a valuable tool to achieve reduction of 
costs and time. More than that, the validation is 
essential to produce reliable results between 
laboratories and for commercial reasons (17). The 
pharmaceutical potential of the association of LA 
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and RSV and the lack of a method for the 
simultaneous detection of these drugs motivated 
the present study, which aims to develop and to 
validate a high performance liquid 
chromatography analysis with ultraviolet detection 
(HLPC-UV) method for simultaneous 
determination of LA and RSV. 
 
Experimental 
 
Materials  
 
The analytical grade reagents used were 
acetonitrile (ACN) from Merck and Pancreac and 
phosphoric acid from Merck. The RSV and LA 
were obtained from Fagron (Brazil) and Pharma 
Nostra (Brazil) respectively, with a purity of 
99.20% e 99.95% respectively. 
 
Instrumental 
 
The RSV and LA were quantified by 
HPLC-UV. The equipment consisted of a 
PerkinElmer S-200 with an UV-vis detector 
(PerkinElmer, Shelton, Connecticut, USA). A 
Phenomenex Phenosphere-Next C18 column (150 
mm x 4.6 mm, 5 μm part size, 1.1E+6 angström 
pore diameter) with a guard column were used in 
the experiments. 
 
Chromatographic Conditions  
 
The wavelength was determined from a 
UV spectrum from 200 to 500 nm in a Shimadzu 
UV-1800 Spectrophotometer, using RSV (0.01 
mM) and LA (0.05 mM) reference solutions. For 
detection, a wavelength of 235nm was selected. 
The mobile phase (MP) consisted of ACN and 
0.01M phosphoric acid (60:40), in a flow rate of 
0.8 mL min. The choice of MP was made from a 
previous study with lipoic acid (Kulkamp et al. 
2009). 
  RSV and LA solutions were diluted to give 
a final theoretical concentration of 1000 μg/mL. 
Thereafter, an aliquot was diluted in the MP. The 
injection volume was 20 μL. 
 
Specificity 
 
 Specificity was evaluated in the presence 
of unloaded lipid core nanocapsules containing: 
caprylic capric triglycerides, sorbitan 
monostearate, poly (Ɛ-caprolactone) and acetone 
as components of organic phase and polysorbate 
80 and ultrapure water as components of the 
aqueous phase, prepared by the method of 
precipitation of preformed polymers (18). For the 
evaluation of specificity, excipients traditionally 
used in solid dosage forms have also been used 
(lactose, magnesium stearate, silicon dioxide and 
starch) to prepare placebo solution. Solutions 
were prepared containing the unloaded lipid core 
nanocapsule, and a solution containing the 
mixture of the excipients: starch, magnesium 
stearate, lactose and mannitol. The solutions were 
diluted in MP and injected under the same method 
validation conditions. After the analysis, the 
chromatograms were compared. 
 
Linearity 
 
The analytical curves were obtained 
through a solution of LA and RSV in the 
concentration of 1000 μg/mL, and prepared using 
5 concentrations of RSV and LA alone or in 
combination. The solutions containing both drugs 
were named RSVass and LAass (Table 1). All 
solutions were prepared in acetronitrile and 
diluted in the MP. The curves were prepared and 
analyzed on three different days. Linearity was 
determined through the linear regression, using 
the method of least squares, and the analysis of 
variance (ANOVA) was calculated, evaluating the 
statistical parameters. The range of the analytical 
curves was based on previous reported methods 
for each isolated substance (19,20). 
 
Limits of detection and quantitation 
 
 The limits of detection and quantification 
were determined mathematically using the 
standard deviation of the value of the intercept 
with the Y axis and slope of three calibration 
curves (21,22). The limits of detection and 
quantification were evaluated based on the 
previously constructed calibration curve. 
 
Precision 
 
 The experiments were evaluated with the 
drugs isolated or in combination. The tested 
concentrations were the central point of the 
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standard curves, which corresponds to the runs 3, 
8 and 13 from Table 1. 
The repeatability (intra-day precision) was 
evaluated by calculating the relative standard 
deviation (RSD) from each drug determination. 
The RSV and LA solutions were analyzed at 
concentrations of 25 μg/mL and 75 μg/mL, 
respectively, alone or in combination in nine 
successive determinations performed on the same 
day. Thus, the results are obtained with the same 
experimental conditions (method, equipment, day 
and analyst). The experimental results were 
expressed as RSD, with an acceptable value of ≤ 
5.0%. 
 The intermediate precision (inter-day) of 
the method was performed at same concentrations 
described above. Three successive determinations 
were performed on three different days. The 
experimental results were considered acceptable 
when RSD ≤ 5.0%. 
 
Accuracy 
 
 The concentrations of RSV and LA tested 
were 5, 25 and 50 μg/mL and 30, 75 and 120 
μg/mL respectively. The association of the drugs 
was also evaluated in the same concentrations. 
The tested concentrations corresponds to the runs 
1,3,5, 6, 8, 10, 11,13 and 15 from Table 1. 
This parameter was determined by the 
recovery test that consisted on adding known 
amounts of reference substance to the placebo 
solution (prepared according to the specificity test 
described above). The samples were diluted in 
acetonitrile and centrifuged at 5000 rpm. An 
aliquot of the supernatant was then collected and 
diluted in the MP, and thus analyzed under the 
described conditions. The analyses were 
performed in triplicates. Accuracy was expressed 
as percentage of RSV and LA recovered in the 
lowest, intermediate and highest concentrations, 
with an acceptable RSD value of ≤ 5.0 %. 
 
Robustness 
 
 The tested concentrations were the central 
point of the standard curves, which corresponds to 
the runs 3, 8 and 13 from Table 1. Solutions with 
concentrations of 25 μg/mL for RSV and 75 
μg/mL for LA were prepared. Three replicates 
were performed on the same day with each 
sample, with small variations in the method. The 
variations were in the ACN supplier (ACN1 - 
Merck and ACN2 - Pancreac), in the MP flow (0.7 
mL/min and 0.9 mL/min) and in the 
ACN/phosphoric acid proportion on the MP 
(65/35 and 55/55). The experimental results were 
expressed as RSD, with an acceptable value of ≤ 
5.0 %. 
 
Table 1. Concentration of RSV and LA analyzed by HPLC-UV, 
when tested isolated or in association. 
Run 
Identification 
Group 
RSV 
(µg/mL) 
LA (µg/mL) 
1 RSV 5 - 
2 15 - 
3 25 - 
4 40 - 
5 50 - 
6 LA - 30 
7 - 50 
8 - 75 
9 - 100 
10 - 120 
11 RSVass / 
LAass 
5 30 
12 15 50 
13 25 75 
14 40 100 
15 50 120 
 
Statistical analysis 
 
 The T test was performed for the paired 
comparisons and ANOVA one way for the other 
comparisons, using GraphPad Prism 5 software. 
 
Results and Discussion 
 
Validation of the quantification method  
 
 The development of the method aimed the 
simultaneous detection of RSV and LA in HPLC-
UV. The UV spectra of the standard solutions of 
RSV (0.01 mM) and LA (0.05 mM) are shown in 
Figure 2. The wavelength of 235nm was selected 
for the simultaneous quantification of the 
compounds to avoid a possible interference from 
the excipients in lower wavelengths and baseline 
destabilization; and, at the same time, to allow the 
detection of both drugs. 
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Figure 2. UV spectra of standard solutions: RSV 0.01mM (black 
line) e LA 0.05mM (red line). 
  
The Figure 3 presents the chromatogram of both 
drugs, injected isolated or simultaneously. The 
concomitant analysis showed a separation with 
resolution of 2.28 and symmetry, with values 
close to 1, both values considered acceptable (21). 
 
 
Figure 3. Chromatograms obtained for the quantification of (a) 
isolated RSV 25µg/mL;(b) isolate LA 75µg/mL; and (c) RSV 
25µg/mL and LA 75µg/mL in association. 
 
Specificity 
 
 The Figure 4 demonstrate the analytical 
method’s ability to measure RSV and LA 
response in the presence of widely used 
pharmaceutical excipients and in the presence of 
an unloaded lipid-core nanocapsules. Thus, the 
method is able to quantify the aimed substances, 
being applicable to distinguish them in the 
presence of different complex matrices (22). 
 
 
Figure 4. Chromatogram obtained from the specificity test for (a) 
unloaded lipid core nanocapsules and (b) excipients. 
Linearity 
 Linearity was evidenced by the linear 
equations for RSV and LA (Table 2). Besides, 
ANOVA was calculated to verify the adjustment 
of the linear method and its results showed 
significant linear regression for both RSV and LA 
considering a p=0.05. In this way, the linearity 
results demonstrated that the results obtained 
experimentally are directly proportional to the 
concentration of the aimed substances in the 
sample within a specified range (22). 
 
 
 
Table2: Validation parameters of the analytical curve obtained from HPLC method for quantitation of lipoic acid and resveratrol. 
 
Samples Equation R Value of F 
LA y = 89907x – 15119 0.996 Fcalculated= 3973.9 >Ftabulated = 4.67 
RSV y = 3372x + 2041 0.997 Fcalculated= 1554.9 >Ftabulated= 4.67 
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 Detection and quantification limits 
 
 Even though LA presents higher 
detection/quantification limit values than RSV, it 
was possible to develop a method for 
simultaneous quantification for both substances. 
The calculated detection limits for both substances 
demonstrated a great sensitivity for the drug 
detection, as shown in Table 3. In the same way, 
the quantification limits allowed quantification of 
low drug concentration, indicating that the method 
is sensitive enough for both drugs and, mainly, 
showing that in the association there was no loss 
in the detection and quantification limits.  
 
Table 3: Quantification (LOQ) and Detection (LOD) limits for 
LA and RSV isolated or in association.  
 
Samples 
QL 
(µg/mL) 
DL 
(µg/mL) 
LA 6.05 2.00 
LAass 6.68 2.21 
RSV 1.68 0.55 
RSVass 1.79 0.59 
 
 
 
 
Precision 
 
The method showed a suitable repeatability (intra-day precision) for LA and RSV, both isolated and 
in association, in the same day, using the same experimental conditions (Table 4). The presence of both 
drugs compared with the isolated drugs did not affect the repeatability, having a p value of 0.0566 for LA 
and 0.1062 for RSV. 
Similarly, the inter-day precision was also adequate. The method variability is on the acceptable 
range (≤ 5%), indicating that the analytical method has an acceptable intermediate precision. This finding 
reflects the ability of the method to withstand variations in results when analysed over three different days 
(ICH, 1996). The experimental results are expressed as relative standard deviation (RSD) and are shown in 
Table 4. The presence of both drugs compared with the isolated drugs did not change the intermediate 
precision, having a p value of 0.0614 for LA and 0.0907 for RSV. 
 
                 Table 4. HPLC-UV method’s intra-day and inter-day precision for RSV and LA isolated or in association. 
  
Intra-day Inter-day 
Samples 
Theoretical 
Concentration 
(µg/ml) 
Experimental 
Concentration (µg/mL) 
± S.D. 
R.S.D (%)a 
Experimental 
Concentration (µg/mL) 
± S.D. 
R.S.D 
(%)b 
LA 75 76.73±1.14
 1.49 76.73±1.14 1.49 
LAass 75 73.20±0.62
 0.86 73.20±0.62 0.86 
RSV 25 25.64±0.31
 1.22 25.64±0.31 1.22 
RSVass 25 25.69±0.47
 1.80 25.69±0.47 1.80 
                                                    a Average of 6 samples 
                                                   b Average of 9 samples 
 
Accuracy 
 
 The samples used for accuracy assay are equivalent to the lowest, intermediate and highest 
concentrations for LA and RSV. The results (Table 5) show the method accuracy, where the concomitant 
presence of the drugs did not change the drug recovery, having a p value of 0.4014 for LA and 0.5587 for 
RSV.
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Table 5. Accuracy test by the recovery assay for RSV and LA isolated or in association, during validation of HPLC method. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
a Average of three samples  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Robustness 
 
 The quantification results for RSV and LA and the experimental range of the selected variables are 
shown in Table 6. No significant RSD alterations were observed in the simultaneous determination of the 
drugs under variations of supplier, modification of MP components proportion and flow, demonstrating the 
robustness of the method. The robustness was evidenced for isolated substances and for the association, 
being observed RSD values lower than 5% for all samples. 
 
Table 6: Method robustness, comparing different solvent manufacturers (ACN1 – Merck and ACN2- Panreac), flow and MP concentrationa for 
RSV and LA isolated or in association. 
 
 ACN 1 ACN 2 
 
Average (%) ± S.D. R.S.D. Average (%) ± S.D. R.S.D. 
LA 100.1±0.62
 0.62 99.9±0.95 0.95 
LAass 99.6±0.84
 0.85 98.7±0.34 0.34 
RSV 98.6±1.40
 1.42 99.3±0.94 0.94 
RSVass 97.8±0.76
 0.78 97.9±0.33 0.33 
 
Flow 0.7mL/min Flow 0.9mL/min 
 
Average (%) ± S.D. R.S.D. Average (%) ± S.D. R.S.D. 
LA 95.1±0.54
 0.56 95.2±0.46 0.58 
LAass 100.3±1.49
 1.48 98.6±0.71 0.72 
RSV 103.4±1.79
 1.73 102.8±1.60 1.55 
RSVass 104.6±0.77
 0.74 102.2±1.37 1.34 
 
MP(65:35) MP(55:45) 
 
Average (%) ± S.D. R.S.D. Average (%) ± S.D. R.S.D. 
LA 100.6±2.60
 2.58 98.6±1.10 1.12 
LAass 98.7±2.12
 2.15 103.3±0.91 0.88 
RSV 103.2±0.38
 0.37 100.2±0.15 0.15 
RSVass 100.2±0.37
 1.22 100.8±0.28 0.28 
a Nominal condition was ACN/phosphoric acid (60:40) at a flow rate of 0.8 mL/min. 
 
  
Samples 
Theoretical 
Concentration (µg/mL) 
Experimental 
Concentration 
(µg/mL) ± S.D. 
Average (%) ± S.D.a R.S.D (%) 
LA 30 29.12±1.32 98.3±1.20 1.22 
50 51.85±1.45 101.1±0.71 0.70 
120 121.38±2.01 101.1±0.81 0.80 
LAass 30 29.39±1.46 98.6±1.27
 1.29 
50 51.93±1.51 101.4±2.10 2.07 
120 119.21±2.23 99.3±1.97 1.98 
RSV 5 5.05±0.69 100.8±2.76
 2.74 
25 26.09±0.45 101.7±3.05 3.00 
50 50.23±0.98 101.3±2.59 2.55 
RSVass 5 6.43±1.25 101.3±2.05
 2.02 
25 25.89±1.22 100.6±1.63 1.62 
50 49.57±1.58 99.6±1.14 1.14 
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Conclusions 
 
The proposed analytical method for 
simultaneous determination of RSV and LA was 
developed under official parameters (21, 22) with 
suitable results of specificity, linearity, precision, 
accuracy and robustness. The method presented a 
suitable detection and quantification limit for both 
substances. It was not observed interferences from 
pharmaceutical excipients as starch, magnesium 
stearate, lactose and mannitol and also lipid-core 
nanocapsules. There was no difference in the 
evaluated parameters when the LA and RSV were 
analysed isolated or in association. The developed 
method can be applied for the analysis of 
pharmaceutical dosage forms containing these 
substances. 
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